Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Arcturus Therapeutics Holdings Inc
(NQ:
ARCT
)
19.06
UNCHANGED
Streaming Delayed Price
Updated: 12:13 PM EDT, Sep 5, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Arcturus Therapeutics Holdings Inc
< Previous
1
2
3
4
5
6
7
8
9
Next >
Arcturus Therapeutics Receives Clearance of an Investigational New Drug Application to U.S. Food and Drug Administration for ARCT-032, an Investigational Inhaled mRNA Therapeutic to Treat Cystic Fibrosis
September 03, 2024
From
Arcturus Therapeutics
Via
Business Wire
Arcturus Therapeutics to Attend Upcoming Investor & Scientific Conferences
August 27, 2024
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
ARCT Stock Earnings: Arcturus Therapeutics Beats EPS, Beats Revenue for Q2 2024
August 05, 2024
ARCT stock results show that Arcturus Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via
InvestorPlace
The Analyst Verdict: Arcturus Therapeutics In The Eyes Of 4 Experts
March 11, 2024
Via
Benzinga
Recap: Arcturus Therapeutics Q4 Earnings
March 07, 2024
Via
Benzinga
Arcturus Therapeutics Announces Second Quarter 2024 Financial Update and Pipeline Progress
August 05, 2024
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Arcturus Therapeutics to Present at Canaccord Genuity 44th Annual Growth Conference
August 01, 2024
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Arcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on August 5, 2024
July 18, 2024
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Arcturus Therapeutics Provides Updates for Ornithine Transcarbamylase (OTC) Deficiency and Cystic Fibrosis (CF) Programs
July 01, 2024
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Cathie Wood-Led Ark Invest Dumps $4.3M Worth Of Nvidia Shares Amid Rebound — Swoops Into Buy Stock Of This Netflix Rival
June 25, 2024
Via
Benzinga
Arcturus Therapeutics Appoints Moncef Slaoui, Ph.D., to Board of Directors
June 20, 2024
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Cathie Wood-Led Ark Invest Sells $1.5M Worth Of Robinhood Shares Amid Muted Bitcoin Market — Also Dumps Zoom Stock Worth $3.3M
June 12, 2024
Ark Invest, led by Cathie Wood, made significant trades on Wednesday involving Robinhood Markets Inc (NASDAQ:HOOD) and Zoom Video Communications Inc (NASDAQ:ZM).
Via
Benzinga
Cathie Wood-Lead Ark Invest Dumps $7.6M Worth Of Robinhood Shares Amid GameStop Buzz, Bitcoin Choppiness
June 10, 2024
On Monday, Cathie Wood-led Ark Invest made a significant move by reducing its holdings in Robinhood Markets Inc (NASDAQ:HOOD). This decision came amidst a period of market fluctuations and followed a...
Via
Benzinga
Arcturus' Inhaled mRNA Therapeutic In Cystic Fibrosis Study Highlights Potential Amid Competitive Landscape: Analyst
June 07, 2024
Arcturus Therapeutics shared Phase 1 and Phase 1b trial results for ARCT-032, an inhaled mRNA therapeutic for cystic fibrosis, showing FEV1 improvements and safety .
Via
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
June 07, 2024
Via
Benzinga
Arcturus Therapeutics Presents New Clinical Data at 47th Annual European Cystic Fibrosis Conference
June 07, 2024
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Arcturus Therapeutics' Early Cystic Fibrosis Trial Results Encouraging - Analyst Cautiously Optimistic
May 28, 2024
Arcturus Therapeutics' early Phase 1 results show ARCT-032 is safe and well-tolerated, with promising improvements in lung function.
Via
Benzinga
Nvidia, Insmed, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday
May 28, 2024
Via
Benzinga
Why Applied DNA Sciences Shares Are Trading Lower By Around 68%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
May 28, 2024
Via
Benzinga
Arcturus Therapeutics Announces Positive Development for Cystic Fibrosis Program
May 28, 2024
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Achilles Therapeutics Announces Research Collaboration with Arcturus Therapeutics to Explore Second-Generation Personalized mRNA Cancer Vaccines
May 22, 2024
From
Achilles Therapeutics PLC
Via
GlobeNewswire
Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics’ COVID-19 Vaccine
May 20, 2024
From
Arcturus Therapeutics
Via
Business Wire
Arcturus Therapeutics to Attend Upcoming Investor & Scientific Conferences
May 15, 2024
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Elon Musk Breaks Ranks With GOP By Praising Genetic Engineering Tech That Helped Fight COVID-19: 'Digital Medicine With Incredible Potential'
May 09, 2024
Elon Musk has come off as a flagbearer of the mRNA technology, which is seen holding out a lot of promise by scientists.
Via
Benzinga
ARCT Stock Earnings: Arcturus Therapeutics Beats EPS, Beats Revenue for Q1 2024
May 08, 2024
ARCT stock results show that Arcturus Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
Via
InvestorPlace
Arcturus Therapeutics Announces First Quarter 2024 Financial Update and Pipeline Progress
May 08, 2024
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 8, 2024
April 25, 2024
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
ARCT Stock Earnings: Arcturus Therapeutics Beats EPS, Misses Revenue for Q4 2023
March 07, 2024
ARCT stock results show that Arcturus Therapeutics beat analyst estimates for earnings per share but missed on revenue for the fourth quarter of 2023.
Via
InvestorPlace
Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline Progress
March 07, 2024
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Earnings Scheduled For March 7, 2024
March 07, 2024
Companies Reporting Before The Bell • CI&T (NYSE:CINT) is estimated to report quarterly earnings at $0.06 per share on revenue of $106.08 million.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.